Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
0-158 |
Sentence |
denotes |
Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. |
T1 |
0-158 |
Sentence |
denotes |
Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition. |
T2 |
159-322 |
Sentence |
denotes |
Alzheimer's disease (AD) is characterized by amyloid-β deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. |
T2 |
159-322 |
Sentence |
denotes |
Alzheimer's disease (AD) is characterized by amyloid-β deposition in amyloid plaques, neurofibrillary tangles, inflammation, neuronal loss, and cognitive deficits. |
T3 |
323-418 |
Sentence |
denotes |
Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. |
T3 |
323-418 |
Sentence |
denotes |
Cannabinoids display neuromodulatory and neuroprotective effects and affect memory acquisition. |
T4 |
419-647 |
Sentence |
denotes |
Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. |
T4 |
419-647 |
Sentence |
denotes |
Here, we studied the impact of cannabinoid receptor type 1 (CB1) deficiency on the development of AD pathology by breeding amyloid precursor protein (APP) Swedish mutant mice (APP23), an AD animal model, with CB1-deficient mice. |
T5 |
648-796 |
Sentence |
denotes |
In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. |
T5 |
648-796 |
Sentence |
denotes |
In addition to the lower body weight of APP23/CB1(-/-) mice, most of these mice died at an age before typical AD-associated changes become apparent. |
T6 |
797-983 |
Sentence |
denotes |
The surviving mice showed a reduced amount of APP and its fragments suggesting a regulatory influence of CB1 on APP processing, which was confirmed by modulating CB1 expression in vitro. |
T6 |
797-983 |
Sentence |
denotes |
The surviving mice showed a reduced amount of APP and its fragments suggesting a regulatory influence of CB1 on APP processing, which was confirmed by modulating CB1 expression in vitro. |
T7 |
984-1090 |
Sentence |
denotes |
Reduced APP levels were accompanied by a reduced plaque load and less inflammation in APP23/CB1(-/-) mice. |
T7 |
984-1090 |
Sentence |
denotes |
Reduced APP levels were accompanied by a reduced plaque load and less inflammation in APP23/CB1(-/-) mice. |
T8 |
1091-1213 |
Sentence |
denotes |
Nevertheless, compared to APP23 mice with an intact CB1, APP23/CB1(-/-) mice showed impaired learning and memory deficits. |
T8 |
1091-1213 |
Sentence |
denotes |
Nevertheless, compared to APP23 mice with an intact CB1, APP23/CB1(-/-) mice showed impaired learning and memory deficits. |
T9 |
1214-1343 |
Sentence |
denotes |
These data argue against a direct correlation of amyloid plaque load with cognitive abilities in this AD mouse model lacking CB1. |
T9 |
1214-1343 |
Sentence |
denotes |
These data argue against a direct correlation of amyloid plaque load with cognitive abilities in this AD mouse model lacking CB1. |
T10 |
1344-1502 |
Sentence |
denotes |
Furthermore, the findings indicate that CB1 deficiency can worsen AD-related cognitive deficits and support a potential role of CB1 as a pharmacologic target. |
T10 |
1344-1502 |
Sentence |
denotes |
Furthermore, the findings indicate that CB1 deficiency can worsen AD-related cognitive deficits and support a potential role of CB1 as a pharmacologic target. |